Sugaya M - Search Results

1

Sugaya M. Sugaya M. Arch Immunol Ther Exp (Warsz). 2015 Apr;63(2):109-15. doi: 10.1007/s00005-014-0313-y. Epub 2014 Sep 3. Arch Immunol Ther Exp (Warsz). 2015. PMID: 25182982 Free article. Review.

2

Differential production of Th1- and Th2-type chemokines by mouse Langerhans cells and splenic dendritic cells.

Fujita H, Asahina A, Sugaya M, Nakamura K, Gao P, Fujiwara H, Tamaki K. Fujita H, et al. Among authors: sugaya m. J Invest Dermatol. 2005 Feb;124(2):343-50. doi: 10.1111/j.0022-202X.2004.23607.x. J Invest Dermatol. 2005. PMID: 15675953 Free article.

3

Chemokines and cutaneous lymphoma.

Sugaya M. Sugaya M. J Dermatol Sci. 2010 Aug;59(2):81-5. doi: 10.1016/j.jdermsci.2010.05.005. Epub 2010 May 27. J Dermatol Sci. 2010. PMID: 20576404 Review.

4

Cutaneous lymphoma and chemokine.

Sugaya M. Sugaya M. Nihon Rinsho Meneki Gakkai Kaishi. 2011;34(2):91-8. doi: 10.2177/jsci.34.91. Nihon Rinsho Meneki Gakkai Kaishi. 2011. PMID: 21628851 Free article. Review. English, Japanese.

5

BAFF levels are increased in lesional skin and sera in patients with cutaneous T-cell lymphoma.

Ohmatsu H, Sugaya M, Miyagaki T, Suga H, Fujita H, Asano Y, Tada Y, Kadono T, Sato S. Ohmatsu H, et al. Among authors: sugaya m. Br J Dermatol. 2012 Aug;167(2):359-67. doi: 10.1111/j.1365-2133.2012.10998.x. Epub 2012 Jul 5. Br J Dermatol. 2012. PMID: 22512719

6

Guidelines for the management of cutaneous lymphomas (2011): a consensus statement by the Japanese Skin Cancer Society - Lymphoma Study Group.

Sugaya M, Hamada T, Kawai K, Yonekura K, Ohtsuka M, Shimauchi T, Tokura Y, Nozaki K, Izutsu K, Suzuki R, Setoyama M, Nagatani T, Koga H, Tani M, Iwatsuki K. Sugaya M, et al. J Dermatol. 2013 Jan;40(1):2-14. doi: 10.1111/j.1346-8138.2012.01639.x. Epub 2012 Aug 20. J Dermatol. 2013. PMID: 22900999

7

A possible contribution of visfatin to the resolution of skin sclerosis in patients with diffuse cutaneous systemic sclerosis via a direct anti-fibrotic effect on dermal fibroblasts and Th1 polarization of the immune response.

Masui Y, Asano Y, Shibata S, Noda S, Akamata K, Aozasa N, Taniguchi T, Takahashi T, Ichimura Y, Toyama T, Sumida H, Yanaba K, Tada Y, Sugaya M, Sato S, Kadono T. Masui Y, et al. Among authors: sugaya m. Rheumatology (Oxford). 2013 Jul;52(7):1239-44. doi: 10.1093/rheumatology/ket010. Epub 2013 Feb 26. Rheumatology (Oxford). 2013. PMID: 23443327

8

CXCL17 Attenuates Imiquimod-Induced Psoriasis-like Skin Inflammation by Recruiting Myeloid-Derived Suppressor Cells and Regulatory T Cells.

Oka T, Sugaya M, Takahashi N, Takahashi T, Shibata S, Miyagaki T, Asano Y, Sato S. Oka T, et al. Among authors: sugaya m. J Immunol. 2017 May 15;198(10):3897-3908. doi: 10.4049/jimmunol.1601607. Epub 2017 Apr 7. J Immunol. 2017. PMID: 28389593

9

CCL17 transgenic mice show an enhanced Th2-type response to both allergic and non-allergic stimuli.

Tsunemi Y, Saeki H, Nakamura K, Nagakubo D, Nakayama T, Yoshie O, Kagami S, Shimazu K, Kadono T, Sugaya M, Komine M, Matsushima K, Tamaki K. Tsunemi Y, et al. Among authors: sugaya m. Eur J Immunol. 2006 Aug;36(8):2116-27. doi: 10.1002/eji.200535564. Eur J Immunol. 2006. PMID: 16856206 Free article.

10

Sézary syndrome treated with narrowband ultraviolet B: time-course measurement of serum levels of CCL17/CCL27.

Masui Y, Sugaya M, Kagami S, Fujita H, Yano S, Nagao M, Komine M, Saeki H, Ihn H, Kikuchi K, Tamaki K. Masui Y, et al. Among authors: sugaya m. Clin Exp Dermatol. 2007 Jan;32(1):57-9. doi: 10.1111/j.1365-2230.2006.02261.x. Clin Exp Dermatol. 2007. PMID: 17305906

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

438 results

Search Page

Filters